companydata.dkcompanydata.dk

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2020

CVR: 32323502

Source: annual report 2020, Danish Business Authority

01/01/2020 – 31/12/2020

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -30,400 and a net result of EUR 196,963 compared with EUR 210,420 the year before. Equity in the 2020 report amounted to EUR 14,601,209. The solvency ratio was 99.9%.

Gross Profit
EUR -30,400
Profit/Loss
EUR 196,963
Equity
EUR 14,601,209
Total Assets
EUR 14,611,690
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020--30K EUR197K EUR14.6M EUR0
2019--2K EUR210K EUR14.4M EUR0
2018-7K EUR371K EUR14.2M EUR0
2017-257K EUR-480K EUR13.8M EUR0
2016-3.2M EUR3.4M EUR14.3M EUR-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: The 2019 annual report is outMay 11, 2020

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2019. Gross profit came to DKK -1,850, and the net result was DKK 210,420.

About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.

Source: annual report 2025, Danish Business Authority